SCHEMBL856383

SCHEMBL856383

Fc1cccc2c(Cl)ncnc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 1/20 0.48
PDE4B Q07343 1/20 0.48
PDE4C Q08493 1/20 0.48
PDE4D Q08499 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.44
PARP1 P09874 1/20 0.44
ADORA3 P0DMS8 1/20 0.42
ADORA2A P29274 1/20 0.42
ADORA1 P30542 1/20 0.42
ALDH1A1 P00352 3/20 0.39
MAPT P10636 2/20 0.39
KDM4E B2RXH2 1/20 0.39
MAPK1 P28482 1/20 0.39
GRM5 P41594 2/20 0.36
LMNA P02545 2/20 0.36
KMT2A Q03164 2/20 0.36
GPR55 Q9Y2T6 1/20 0.36
SSTR4 P31391 1/20 0.36
AURKA O14965 3/20 0.35
RPS6KB1 P23443 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29460991 1.00 PDE4A (0.48) PDE4APDE4BPDE4CPDE4DSMN1; SMN2
SCHEMBL858030 0.79 PDE4A (0.52) PDE4APDE4BPDE4CPDE4DSMN1; SMN2
SCHEMBL29416439 0.79 PDE4A (0.52) PDE4APDE4BPDE4CPDE4DSMN1; SMN2
SCHEMBL13783327 0.76 PARP1 (0.44) PARP1ALDH1A1MAPTLMNAKMT2A
SCHEMBL31446733 0.76 PARP1 (0.44) SMN1; SMN2PARP1ALDH1A1MAPTKDM4E
SCHEMBL22221946 0.76 PARP1 (0.44) PARP1MAPTKDM4EMAPK1LMNA
SCHEMBL29728040 0.76 PI4KA (0.48) SMN1; SMN2PARP1
SCHEMBL20399046 0.76 PI4KA (0.48) SMN1; SMN2PARP1
SCHEMBL10292146 0.76 PDE4A (0.48) PDE4APDE4BPDE4CPDE4DSMN1; SMN2
SCHEMBL3763540 0.76 PDE4A (0.48) PDE4APDE4BPDE4CPDE4DSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12522595-B2 Bicyclic ether O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors BIOGEN MA INC. (US) 2026-01-13 US disclosed
US-12390463-B2 Dosage forms and regimens for amino acid compounds PLIANT THERAPEUTICS, INC. (US) 2025-08-19 US disclosed
US-20250223288-A1 AMINO ACID COMPOUNDS AND METHODS OF USE PLIANT THERAPEUTICS, INC. 2025-07-10 US disclosed
WO-2025067384-A1 AMINO ACID INTEGRIN INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF 成都微芯药业有限公司 2025-04-03 WO disclosed
EP-4520329-A2 TREATMENT OF RESPIRATORY DISEASES WITH AMINO ACID COMPOUNDS Pliant Therapeutics, Inc. (US) 2025-03-12 EP disclosed
EP-4509512-A2 AMINO ACID COMPOUNDS AND METHODS OF USE Pliant Therapeutics, Inc. (US) 2025-02-19 EP disclosed
CN-113195053-B Amino acid compounds and methods of use 普利安特治疗公司 2024-08-30 CN disclosed
US-20240270742-A1 SUBSTITUTED AMINO ACIDS AS INTEGRIN INHIBITORS PLIANT THERAPEUTICS INC (US) 2024-08-15 US disclosed
US-11952376-B2 Substituted amino acids as integrin inhibitors PLIANT THERAPEUTICS, INC. (US) 2024-04-09 US disclosed
EP-4329755-A1 EXPANDED DOSAGE REGIMENS FOR INTEGRIN INHIBITORS Pliant Therapeutics, Inc. (US) 2024-03-06 EP disclosed
US-20100298290-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2010-11-25 US disclosed
WO-2010135524-A1 BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES EXELIXIS, INC. (US) 2010-11-25 WO disclosed
CN-1052379-C Quinazoline derisatives DOWELANCO (US) 2000-05-17 CN disclosed
EP-0326329-B1 Quinazoline derivatives useful as insecticides. DOW AGROSCIENCES LLC (US) 1998-10-28 EP disclosed
US-5411963-A Plant fungicides, miticides, insecticides DOWELANCO (US) 1995-05-02 US disclosed
US-5326766-A Fungicide, nematocide, insecticide, miticide DOWELANCO 1994-07-05 US disclosed
WO-1994004526-A1 4-[2-(4-(2-PYRIDINYLOXY)PHENYL)ETHOXY]-QUINAZOLINE AND ANALOGUES THEREOF DOWELANCO (US) 1994-03-03 WO disclosed
WO-1994004527-A1 PYRIDYLETHOXY-, PYRIDYLETHYLAMINO-, AND PYRIDYLPROPYL-DERIVATIVES OF QUINOLINE AND QUINAZOLINE AS INSECTICIDES AND FUNGICIDES DOWELANCO (US) 1994-03-03 WO disclosed
CN-1035825-A Quinazoline derivant LILLY CO ELI (US) 1989-09-27 CN disclosed
EP-0326329-A2 Quinazoline derivatives DowElanco (US) 1989-08-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298290-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA PDE4A 1259/4885PDE4B 1027/4885PDE4C 1349/4885
US-12390463-B2 Dosage forms and regimens for amino acid compounds ITGB6, ITGA6, ITGAV PDE4A 3891/4885PDE4B 3849/4885PDE4C 4382/4885
US-20250223288-A1 AMINO ACID COMPOUNDS AND METHODS OF USE ITGB6, ITGA6, ITGA5 PDE4A 3921/4885PDE4B 3861/4885PDE4C 4299/4885
US-11952376-B2 Substituted amino acids as integrin inhibitors ITGB6, ITGA1, ITGB1 PDE4A 4765/4885PDE4B 4733/4885PDE4C 4812/4885
US-20240270742-A1 SUBSTITUTED AMINO ACIDS AS INTEGRIN INHIBITORS ITGB6, ITGA1, ITGB1 PDE4A 4765/4885PDE4B 4733/4885PDE4C 4812/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.